Journal
WORLD JOURNAL OF CLINICAL CASES
Volume 8, Issue 1, Pages 97-102Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.12998/wjcc.v8.i1.97
Keywords
Pembrolizumab; Pulmonary sarcomatoid carcinoma; Programmed death-ligand 1; Platinum-based chemotherapy; Non-small-cell lung cancer; Overall survival; Case report
Categories
Ask authors/readers for more resources
BACKGROUND Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma (PSC), a rare, previously rapidly fatal subtype of non-small-cell lung cancer. CASE SUMMARY We report the case of a 69-year-old man presented with respiratory distress caused by a large left upper lung lobe mass diagnosed as PSC with programmed death-ligand 1 expressed on more than 50 percent of tumor cells. The patient was started on pembrolizumab and, after 5 cycles, there was a more than 80 percent decrease in the size of the tumor mass. Further decrease was seen at the end of 10 cycles. The patient has been tolerating pembrolizumab well, with no limiting side-effects. Fourteen months after first coming into the hospital, he remains asymptomatic. CONCLUSION Pembrolizumab appears as a viable emerging treatment for PSC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available